Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.

American journal of hematology - 1 Sept 2002

Ruggeri Marco, Gisslinger Heinz, Tosetto Alberto, Rintelen Claudia, Mannhalter Christine, Pabinger Ingrid, Heis Navide, Castaman Giancarlo, Missiaglia Edoardo, Lechner Klaus, Rodeghiero Francesco

Abstract excerpt

Polycythemia Vera (PV) and Essential Thrombocythemia (ET) are chronic myeloproliferative disorders complicated by a high incidence of thrombotic complications. Extensive coagulation studies failed to demonstrate a consistent pattern of abnormalities associated with thrombosis. Recently, a poor anticoagulant response to activated protein C (APC), due to a mutation of factor V (FV Leiden), has been identified as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Activated Protein C Resistance
Share to Anticoagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Austria

Share to Polycythemia Vera

Share to Thrombocythemia, Essential

Share to Thrombophilia

Share to Venous Thrombosis

Share to Warfarin

Source

Identifiers

PMID: 12221665
DOI: 10.1002/ajh.10153

Genes

APC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.PMID 12221665Read ↗

Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemiaSemantic proximity Read ↗

Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia.Semantic proximity Read ↗

It is time to change thrombosis risk assessment for PV and ET?Semantic proximity Read ↗

JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation statusSemantic proximity Read ↗

Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.Semantic proximity Read ↗

Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation.Semantic proximity Read ↗

New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism.Semantic proximity Read ↗

JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.